Drugs / S 55746
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02603445 | Nov 2015 → Jul 2018 | mantle cell lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02920541 | Jan 2015 → May 2018 | acute myeloid leukemia, myelodysplastic syndrome | Servier | Completed | No outcome recorded |
| Phase 1 | NCT02920697 | Mar 2014 → Oct 2018 | B-cell chronic lymphocytic leukemia, plasma cell myeloma | Servier | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S 55746 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02920697 ↗ |
| Known as | BCL201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603445 ↗ |
| Known as | S 055746 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02920541 ↗ |
| Action | Inhibit | “selective Bcl-2 inhibitor S 055746” NCT02920541 ↗ |
| Route | Oral | “S 055746, per os administration” NCT02920541 ↗ |
| Target | BCL2 | “selective Bcl-2 inhibitor S 055746” NCT02920541 ↗ |